$DVA
DAVITA INC. Stock $dva

$dva Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000092706624000128 Filed on August 06, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$3.264B	$3.187B
YoY Change	4.56%	6.21%
Cost Of Revenue	$2.152B	$2.142B
YoY Change	4.09%	4.21%
Gross Profit	$1.112B	$1.044B
YoY Change	5.47%	10.58%
Gross Profit Margin	34.06%	32.77%
Selling, General & Admin	$393.5M	$367.8M
YoY Change	4.42%	1.05%
% of Gross Profit	35.4%	35.22%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$187.0M	$175.7M
YoY Change	-0.77%	-4.36%
% of Gross Profit	16.82%	16.82%
Operating Expenses	$580.5M	$543.5M
YoY Change	2.7%	-0.76%
Operating Profit	$534.9M	$506.4M
YoY Change	7.85%	24.95%
Interest Expense	-$130.9M	-$92.27M
YoY Change	44.05%	-2.93%
% of Operating Profit	-24.47%	-18.22%
Other Income/Expense, Net	-$16.78M	-$27.48M
YoY Change	-14.61%	-2101.38%
Pretax Income	$373.4M	$371.4M
YoY Change	-1.26%	25.83%
Income Tax	$77.67M	$71.69M
% Of Pretax Income	20.8%	19.3%
Net Earnings	$214.7M	$222.7M
YoY Change	-12.95%	24.62%
Net Earnings / Revenue	6.58%	6.99%
Basic Earnings Per Share	$2.56	$2.56
Diluted Earnings Per Share	$2.50	$2.50
COMMON SHARES
Basic Shares Outstanding	83.90M shares	87.70M shares
Diluted Shares Outstanding	85.80M shares	88.95M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.126B	$469.0M
YoY Change	122.24%	21.51%
Cash & Equivalents	$1.071B	$416.5M
Short-Term Investments	$54.84M	$52.47M
Other Short-Term Assets	$184.9M	$169.9M
YoY Change	-1.03%	-8.08%
Inventory	$129.0M	$126.8M
Prepaid Expenses
Receivables	$2.267B	$2.303B
Other Receivables	$359.5M	$420.6M
Total Short-Term Assets	$4.037B	$3.467B
YoY Change	28.76%	15.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.940B	$2.982B
YoY Change	-5.1%	-5.58%
Goodwill	$7.228B	$7.201B
YoY Change	1.97%	1.34%
Intangibles	$197.9M	$191.5M
YoY Change	6.72%	-0.19%
Long-Term Investments	$464.3M	$485.5M
YoY Change	-23.97%	-24.06%
Other Assets	$219.0M	$240.5M
YoY Change	-27.53%	-23.41%
Total Long-Term Assets	$13.47B	$13.56B
YoY Change	-2.37%	-2.85%
TOTAL ASSETS
Total Short-Term Assets	$4.037B	$3.467B
Total Long-Term Assets	$13.47B	$13.56B
Total Assets	$17.50B	$17.03B
YoY Change	3.4%	0.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$488.2M	$493.5M
YoY Change	12.13%	15.34%
Accrued Expenses	$1.211B	$1.050B
YoY Change	4.04%	2.43%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$296.3M	$538.0M
YoY Change	172.9%	432.07%
Total Short-Term Liabilities	$2.944B	$2.995B
YoY Change	16.0%	24.61%
LONG-TERM LIABILITIES
Long-Term Debt	$9.260B	$8.452B
YoY Change	11.77%	-1.71%
Other Long-Term Liabilities	$183.0M	$179.0M
YoY Change	-1.03%	-2.25%
Total Long-Term Liabilities	$183.0M	$179.0M
YoY Change	-1.03%	-2.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.944B	$2.995B
Total Long-Term Liabilities	$183.0M	$179.0M
Total Liabilities	$15.28B	$14.60B
YoY Change	8.37%	1.89%
SHAREHOLDERS EQUITY
Retained Earnings	$1.275B	$1.061B
YoY Change	78.27%	126.28%
Common Stock	$295.7M	$383.3M
YoY Change	-46.5%	-31.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.022B	$615.9M
YoY Change
Treasury Stock Shares
Shareholders Equity	$386.7M	$632.9M
YoY Change
Total Liabilities & Shareholders Equity	$17.50B	$17.03B
YoY Change	3.4%	0.39%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	$214.7M	$222.7M
YoY Change	-12.95%	24.62%
Depreciation, Depletion And Amortization	$187.0M	$175.7M
YoY Change	-0.77%	-4.36%
Cash From Operating Activities	$810.4M	$798.8M
YoY Change	22.58%	77.48%
INVESTING ACTIVITIES
Capital Expenditures	$139.0M	$124.7M
YoY Change	1.63%	0.18%
Acquisitions
YoY Change
Other Investing Activities	-$7.445M	-$37.03M
YoY Change	148.75%	-83.36%
Cash From Investing Activities	-$146.5M	-$161.8M
YoY Change	4.78%	-53.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-7.858M	-563.3M
YoY Change	-98.01%	481.7%
NET CHANGE
Cash From Operating Activities	810.4M	798.8M
Cash From Investing Activities	-146.5M	-161.8M
Cash From Financing Activities	-7.858M	-563.3M
Net Change In Cash	656.1M	73.79M
YoY Change	417.5%	1098.33%
FREE CASH FLOW
Cash From Operating Activities	$810.4M	$798.8M
Capital Expenditures	$139.0M	$124.7M
Free Cash Flow	$671.4M	$674.1M
YoY Change	28.04%	107.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	25723000	usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	90000	usd
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	383235000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1060613000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	85081000	shares
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	dva	Corporate Integrity Agreement Period CorporateIntegrityAgreementPeriod	P5Y
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	88824000	shares
CY2024Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4774000	shares
CY2024Q2	us-gaap	Treasury Stock Value TreasuryStockValue	615948000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-195090000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	632900000	usd
CY2024Q2	us-gaap	Minority Interest MinorityInterest	217116000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	850016000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17025572000	usd
	us-gaap	Profit Loss ProfitLoss	605732000	usd
	us-gaap	Profit Loss ProfitLoss	417045000	usd
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	362744000	usd
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	361743000	usd
	dva	Loss On Extinguishment Of Debt LossOnExtinguishmentOfDebt	2445000	usd
	dva	Loss On Extinguishment Of Debt LossOnExtinguishmentOfDebt	7132000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	48832000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	55197000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-28643000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-16178000	usd
	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-54748000	usd
	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-14571000	usd
	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain	35147000	usd
	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain	0	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-16570000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	5160000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	193093000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-141503000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-22422000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	116000	usd
	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	13898000	usd
	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	-33182000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	3367000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	607000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-38998000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-40615000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-122817000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-68800000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1219000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	17242000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-8097000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	5200000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-6642000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-8675000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	664010000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	912664000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	245740000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	272204000	usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	157783000	usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	2575000	usd
	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	12779000	usd
	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	21198000	usd
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	309000	usd
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	30419000	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	3411000	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	6366000	usd
	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	7082000	usd
	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	94414000	usd
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	4564000	usd
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	3873000	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	700000	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	273336000	usd
	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	6554000	usd
	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	1758000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-376964000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-463657000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	3275533000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2136873000	usd
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	2661145000	usd
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	2347120000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	19993000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	45009000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	612614000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	107210000	usd
	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	124178000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	86277000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	43612000	usd
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	7621000	usd
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	6946000	usd
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	860000	usd
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	50962000	usd
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	40751000	usd
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	7610000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-243976000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-372748000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-4458000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6922000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	38612000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	83181000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	464634000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	338989000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	503246000	usd
CY2024Q2	us-gaap	Revenues Revenues	3186722000	usd
CY2023Q2	us-gaap	Revenues Revenues	3000369000	usd
	us-gaap	Revenues Revenues	6257277000	usd
	us-gaap	Revenues Revenues	5873068000	usd
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	31309000	usd
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	23303000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	222676000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	178691000	usd
	us-gaap	Net Income Loss NetIncomeLoss	462325000	usd
	us-gaap	Net Income Loss NetIncomeLoss	294238000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	86899000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	90984000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	87337000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	90742000	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2051000	shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2434000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2412000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2210000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	88950000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	93418000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	89749000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	92952000	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.56
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.96
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.29
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.24
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.50
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.91
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.15
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.17
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4000	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	280000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	197000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	787000	shares
CY2024Q2	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	15293000	usd
CY2024Q2	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	37179000	usd
CY2024Q2	us-gaap	Marketable Securities MarketableSecurities	52472000	usd
CY2023Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	22109000	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	37391000	usd
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	59500000	usd
CY2024Q2	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	15293000	usd
CY2024Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	20693000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	7110000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	11610000	usd
CY2024Q2	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	0	usd
CY2024Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	31779000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	14999000	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	47890000	usd
CY2024Q2	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	15293000	usd
CY2024Q2	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	37179000	usd
CY2024Q2	us-gaap	Marketable Securities MarketableSecurities	52472000	usd
CY2023Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	22109000	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	37391000	usd
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	59500000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	7076610000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	26083000	usd
CY2023	us-gaap	Goodwill Translation And Purchase Accounting Adjustments GoodwillTranslationAndPurchaseAccountingAdjustments	36310000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	7112560000	usd
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	137817000	usd
	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	1687000	usd
	us-gaap	Goodwill Translation And Purchase Accounting Adjustments GoodwillTranslationAndPurchaseAccountingAdjustments	-47291000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	7201399000	usd
CY2024Q2	us-gaap	Goodwill Gross GoodwillGross	7346904000	usd
CY2024Q2	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	145505000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	7201399000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2024Q2	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	453709000	usd
CY2023Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	545848000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	8445980000	usd
CY2023Q4	dva	Discount Premium And Deferred Financing Costs DiscountPremiumAndDeferredFinancingCosts	54347000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	8391633000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	123299000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	8268334000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	465033000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	147057000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1040219000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	134619000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	1295333000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	41171000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	5924763000	usd
CY2024Q2	dva	Leverage Ratio Covenant LeverageRatioCovenant	4.00
CY2024Q2	dva	Leverage Ratio Covenant Through Jun302026 LeverageRatioCovenantThroughJun302026	5.00
CY2024Q2	dva	Leverage Ratio Covenant After Jun302026 LeverageRatioCovenantAfterJun302026	4.50
CY2024Q2	dva	Leverage Ratio Covenant After Jun302026 Subject To Increase During Four Fiscal Quarters Following A Material Acquisition LeverageRatioCovenantAfterJun302026SubjectToIncreaseDuringFourFiscalQuartersFollowingAMaterialAcquisition	5.00
CY2024Q2	dva	Debt Prepayment Extinguishment And Modification Costs DebtPrepaymentExtinguishmentAndModificationCosts	9732000	usd
CY2024Q2	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0427
	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0439
CY2024Q2	us-gaap	Longterm Debt Weighted Average Interest Rate LongtermDebtWeightedAverageInterestRate	0.0433
CY2024Q2	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.55
CY2024Q2	dva	Long Term Debt Percentage Bearing Economically Fixed Interest Rate LongTermDebtPercentageBearingEconomicallyFixedInterestRate	0.93
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">contingencies</span><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a highly regulated industry and is a party to various lawsuits, demands, claims, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits, governmental investigations (which frequently arise from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits) and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings, including, without limitation, those described below. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. As of June 30, 2024 and December 31, 2023, the Company’s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company’s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.</span></div><div style="margin-top:9pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Governmental Inquiries and Related Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2017 U.S. Attorney Colorado Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In November 2017, the U.S. Attorney’s Office, District of Colorado informed the Company of an investigation it was conducting into possible federal healthcare offenses involving DaVita Kidney Care, as well as several of the Company’s wholly-owned subsidiaries. In addition to DaVita Kidney Care, the matter included an investigation into DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In each of August 2018, May 2019, and July 2021, the Company received a Civil Investigative Demand (CID) pursuant to the FCA from the U.S. Attorney's Office relating to this investigation. In May 2020, the Company sold its interest in Lifeline, but the Company retained certain liabilities of the Lifeline business, including those related to this investigation. On May 6, 2024, the Company finalized and executed a settlement agreement with the government and the relator in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> matter that included a settlement amount of $34,487 for this matter. On May 7, 2024, the government notified the U.S. District Court, District of Colorado of its decision to intervene for purposes of settlement in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Kogod v. DaVita Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government and the relator agreed to voluntarily dismiss all substantive claims in the matter, and, on July 18, 2024, the District Court dismissed all claims except for the relator’s statutory claim for expenses, attorney’s fees, and costs. The Company disputes the relator’s request for expenses, attorney’s fees, and costs, and intends to defend accordingly.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 U.S. Attorney New Jersey Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In March 2020, the U.S. Attorney’s Office, District of New Jersey served the Company with a subpoena and a CID relating to an investigation being conducted by that office and the U.S. Attorney’s Office, Eastern District of Pennsylvania. The subpoena and CID request information on several topics, including certain of the Company’s joint venture arrangements with physicians and physician groups, medical director agreements, and compliance with its five-year Corporate Integrity Agreement, the term of which expired October 22, 2019. In November 2022, the Company learned that, on April 1, 2022, the U.S. Attorney’s Office for the District of New Jersey notified the U.S. District Court for the District of New Jersey of its decision not to elect to intervene in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Doe v. DaVita Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and filed a Stipulation of Dismissal. On April 13, 2022, the U.S. District Court for the District of New Jersey dismissed the case without prejudice. On October 12, 2022, the U.S. Attorney’s Office for the Eastern District of Pennsylvania notified the U.S. District Court, Eastern District of Pennsylvania, of its decision not to elect to intervene at this time in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Bayne v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The court then unsealed an amended complaint, which alleges violations of federal and state False Claims Acts, by order dated October 14, 2022. On November 8, 2023, the private party relator filed a fourth amended complaint. On November 29, 2023, the Company filed a motion to dismiss the fourth amended complaint. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 California Department of Insurance Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In April 2020, the California Department of Insurance (CDI) sent the Company an Investigative Subpoena relating to an investigation being conducted by that office. CDI issued a superseding subpoena in September 2020 and an additional subpoena in September 2021. Those subpoenas request information on a number of topics, including but not limited to the Company’s communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF), analyses of the potential impact of patients’ decisions to change insurance providers, and documents relating to donations or contributions to the AKF. The Company is continuing to cooperate with CDI in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 District of Columbia Office of Attorney General Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In January 2023, the Office of the Attorney General for the District of Columbia issued a CID to the Company in connection with an antitrust investigation into the AKF. The CID covers the period from January 1, 2016 to the present. The CID requests information on a number of topics, including but not limited to the Company’s communications with AKF, documents relating to donations to the AKF, and communications with patients, providers, and insurers regarding the AKF. The Company is cooperating with the government in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2024 Federal Trade Commission Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In April 2024, the Company received from the Federal Trade Commission (FTC) two CIDs in connection with an industry investigation under Section 5 of the Federal Trade Commission Act regarding the acquisition of Medical Director services and provision of dialysis services. The CIDs cover the period from January 1, 2016 to the present and generally seek information relating to restrictive covenants, such as non-competes, with physicians. The Company is cooperating with the government in this investigation.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and ongoing discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies, many of which relate to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company’s reputation, required changes to the Company’s business practices, an impact on the Company's various relationships and/or contracts related to the Company's business, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.</span></div><div style="margin-top:9pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Antitrust Indictment and Putative Class Action Suit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On July 14, 2021, an indictment was returned by a grand jury in the U.S. District Court, District of Colorado against the Company and its former chief executive officer in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> alleging that purported agreements entered into by DaVita's former chief executive officer not to solicit senior-level employees violated Section 1 of the Sherman Act. On April 15, 2022, a jury returned a verdict in the Company’s favor, acquitting both the Company and its former chief executive officer on all counts. On April 20, 2022, the court entered judgments of acquittal and closed the case. On August 9, 2021, DaVita Inc. and its former chief executive officer were added as defendants in a consolidated putative class action complaint in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Outpatient Medical Center Employee Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. District Court, Northern District of Illinois. This class action complaint asserts that the defendants violated Section 1 of the Sherman Act and seeks to bring an action on behalf of certain groups of individuals employed by the Company between February 1, 2012 and January 5, 2021. On September 26, 2022, the court denied the Company's motion to dismiss. The Company disputes the allegations in the class action complaint, as well as the asserted violations of the Sherman Act, and intends to defend this action accordingly.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> * </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 8, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company’s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management’s attention and result in significant legal expense, and may result in the diversion of significant operational resources, may impact the Company's various relationships and/or contracts related to the Company's business or otherwise harm the Company’s business, results of operations, financial condition, cash flows or reputation.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> * *</span></div>
CY2019Q4	dva	Corporate Integrity Agreement Expiration Date CorporateIntegrityAgreementExpirationDate	2019-10-22
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	174104000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M24D
CY2021Q4	srt	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	2000000000	usd
CY2024Q2	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	60065000	usd
CY2024Q2	dva	Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average Ebitda Multiple PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple	205000000	usd
CY2024Q2	us-gaap	Revenues Revenues	3186722000	usd
CY2023Q2	us-gaap	Revenues Revenues	3000369000	usd
	us-gaap	Revenues Revenues	6257277000	usd
	us-gaap	Revenues Revenues	5873068000	usd
CY2024Q2	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	25196000	usd
CY2023Q2	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	33864000	usd
	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	55586000	usd
	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	58452000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	506398000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	405291000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	990243000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	716936000	usd
CY2024Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	97747000	usd
CY2023Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	103507000	usd
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	197165000	usd
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	204281000	usd
CY2024Q2	dva	Debt Prepayment Extinguishment And Modification Costs DebtPrepaymentExtinguishmentAndModificationCosts	9732000	usd
CY2023Q2	dva	Debt Prepayment Extinguishment And Modification Costs DebtPrepaymentExtinguishmentAndModificationCosts	7962000	usd
	dva	Debt Prepayment Extinguishment And Modification Costs DebtPrepaymentExtinguishmentAndModificationCosts	9732000	usd
	dva	Debt Prepayment Extinguishment And Modification Costs DebtPrepaymentExtinguishmentAndModificationCosts	7962000	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-27479000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1373000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-40120000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5125000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	371440000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	295195000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	743226000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	509818000	usd
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	175661000	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	183672000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	362744000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	361743000	usd
	us-gaap	Segment Expenditure Addition To Long Lived Assets SegmentExpenditureAdditionToLongLivedAssets	245740000	usd
	us-gaap	Segment Expenditure Addition To Long Lived Assets SegmentExpenditureAdditionToLongLivedAssets	272204000	usd
	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0000927066-24-000128-index-headers.html	Edgar Link	pending
0000927066-24-000128-index.html	Edgar Link	pending
0000927066-24-000128.txt	Edgar Link	pending
0000927066-24-000128-xbrl.zip	Edgar Link	pending
dva-20240630.htm	Edgar Link	pending
dva-20240630.xsd	Edgar Link	pending
dva-20240630_g1.jpg	Edgar Link	pending
dva-63024ex31110xq.htm	Edgar Link	pending
dva-63024ex31210xq.htm	Edgar Link	pending
dva-63024ex32110xq.htm	Edgar Link	pending
dva-63024ex32210xq.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
dva-20240630_cal.xml	Edgar Link	unprocessable
dva-20240630_def.xml	Edgar Link	unprocessable
dva-20240630_lab.xml	Edgar Link	unprocessable
dva-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
dva-20240630_htm.xml	Edgar Link	completed
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DVA
DAVITA INC. Stock $dva

2024 Q3 Form 10-Q Financial Statement

#000092706624000128 Filed on August 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA DAVITA INC. Stock $dva

2024 Q3 Form 10-Q Financial Statement

#000092706624000128 Filed on August 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA
DAVITA INC. Stock $dva